Elamipretide

• CAT Number: I004736
• CAS Number: 736992-21-5
• Molecular Formula: C32H49N9O5
• Molecular Weight: 639.79
• Purity: ≥95%
• Target: cardiolipin peroxidase inhibitor
• Solubility: DMSO ≥ 29 mg/mL
• Storage: -20°C
• IUPAC Name: (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide
• InChI: InChI=1S/C32H49N9O5/c1-19-15-22(42)16-20(2)23(19)18-27(41-29(44)24(34)11-8-14-38-32(36)37)31(46)39-25(12-6-7-13-33)30(45)40-26(28(35)43)17-21-9-4-3-5-10-21/h3-5,9-10,15-16,24-27,42H,6-8,11-14,17-18,33-34H2,1-2H3,(H2,35,43)(H,39,46)(H,40,45)(H,41,44)(H4,36
• InChIKey: SFVLTCAESLKEHH-WKAQUBQDSA-N
• SMILES: O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H](CCCCN)NC([C@H](CC2=C(C)C=C(O)C=C2C)NC([C@@H](CCCNC(N)=N)N)=O)=O)=O

Elamipretide(CAT: I004736) is a cardiolipin peroxidase inhibitor and a mitochondria-targeting peptide that improves Left Ventricular and Mitochondrial Function. Elamipretide can alleviate mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells. This product is mainly used in medical research and development and other scientific research purposes.

Overview of Clinical Research

Elamipretide is a cardiolipin modulator and a free radical scavenger as well as a mitochondrial permeability transition pore inhibitor. It has been granted for the orphan drug status in Mitochondrial myopathies, Leber's hereditary optic atrophy and Barth syndrome. The Phase II clinical trials for the treatment of Chronic heart failure and Mitochondrial myopathies are ongoing.

Reference

1: Saad A, Herrmann SMS, Eirin A, Ferguson CM, Glockner JF, Bjarnason H, McKusick MA, Misra S, Lerman LO, Textor SC. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circ Cardiovasc Interv. 2017 Sep;10(9). pii: e005487. doi: 10.1161/CIRCINTERVENTIONS.117.005487. PubMed PMID: 28916603; PubMed Central PMCID: PMC5659347.
2: Hortmann M, Robinson S, Mohr M, Mauler M, Stallmann D, Reinöhl J, Duerschmied D, Peter K, Carr J, Gibson CM, Bode C, Ahrens I. The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2017 May 1:2048872617710789. doi: 10.1177/2048872617710789. [Epub ahead of print] PubMed PMID: 28534645.
3: Wu J, Hao S, Sun XR, Zhang H, Li H, Zhao H, Ji MH, Yang JJ, Li K. Elamipretide (SS-31) Ameliorates Isoflurane-Induced Long-Term Impairments of Mitochondrial Morphogenesis and Cognition in Developing Rats. Front Cell Neurosci. 2017 Apr 25;11:119. doi: 10.3389/fncel.2017.00119. eCollection 2017. PubMed PMID: 28487636; PubMed Central PMCID: PMC5403826.
4: Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2):e002206. doi: 10.1161/CIRCHEARTFAILURE.115.002206. PubMed PMID: 26839394; PubMed Central PMCID: PMC4743543.